Amicus Therap Us Drug Patent Portfolio
Amicus Therap Us owns 2 orange book drugs protected by 68 US patents Given below is the list of Amicus Therap Us's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11833164 | Methods of treating Fabry disease in patients having a mutation in the GLA gene | 11 Jan, 2042 | Active |
| US11633388 | Methods of treating Fabry patients having renal impairment | 25 Mar, 2039 | Active |
| US11622962 | Methods of treating Fabry patients having renal impairment | 17 Mar, 2039 | Active |
| US11642334 | Methods of treating Fabry patients having renal impairment | 20 Feb, 2039 | Active |
| US11826360 | Methods of treating Fabry patients having renal impairment | 16 Feb, 2039 | Active |
| US11357784 | Use of migalastat for treating Fabry disease in pregnant patients | 06 Feb, 2039 | Active |
| US11903938 | Methods of treating Fabry patients having renal impairment | 17 Aug, 2038 | Active |
| US10251873 | Methods of treating fabry patients having renal impairment | 30 May, 2038 | Active |
| US10471053 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10792278 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10792279 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10799491 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10806727 | Methods of treating fabry patients having renal impairment | 30 May, 2038 | Active |
| US10849889 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10849890 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10857141 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10857142 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10874655 | Methods of treating fabry patients having renal impairment | 30 May, 2038 | Active |
| US10874656 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10874657 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11278536 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11278537 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11278538 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11278539 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11278540 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11304940 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11357761 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11357762 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11357763 | Methods of treating fabry patients having renal impairment | 30 May, 2038 | Active |
| US11357764 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11357765 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11376244 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11389436 | Methods of treating fabry patients having renal impairment | 30 May, 2038 | Active |
| US11389437 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11426396 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11458128 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11612593 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11612594 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11633387 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11666564 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11786516 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US11813255 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US12042488 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US12042489 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US12042490 | Methods of treating Fabry patients having renal impairment | 30 May, 2038 | Active |
| US10857212 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | 12 Aug, 2037 | Active |
| US10076514 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene | 15 Mar, 2037 | Active |
| US11234972 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene | 15 Mar, 2037 | Active |
| US11278601 | Augmented acid alpha-glucosidase for the treatment of Pompe disease | 29 Dec, 2036 | Active |
| US10208299 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | 30 Sep, 2035 | Active |
| US10961522 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | 30 Sep, 2035 | Active |
| US11753632 | Highly potent acid alpha-glucosidase with enhanced carbohydrates | 30 Sep, 2035 | Active |
| US10512677 | High concentration alpha-glucosidase compositions for the treatment of pompe disease | 07 Mar, 2033 | Active |
| US11278599 | High concentration alpha-glucosidase compositions for the treatment of Pompe disease | 07 Mar, 2033 | Active |
| USRE48608 | Method to predict response to pharmacological chaperone treatment of diseases | 20 Oct, 2031 | Active |
| US10813921 | Method to predict response to pharmacological chaperone treatment of diseases | 12 Feb, 2029 | Active |
| US8592362 | Method to predict response to pharmacological chaperone treatment of diseases | 12 Feb, 2029 | Active |
| US9095584 | Method to predict response to pharmacological chaperone treatment of diseases | 12 Feb, 2029 | Active |
| US10525045 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | 28 Apr, 2028 | Active |
| US10925866 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | 28 Apr, 2028 | Active |
| US11033538 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | 28 Apr, 2028 | Active |
| US9999618 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | 28 Apr, 2028 | Active |
| US10383864 | Methods for treatment of Fabry disease | 16 May, 2027 | Active |
| US10406143 | Methods for treatment of fabry disease | 16 May, 2027 | Active |
| US11241422 | Methods for treatment of Fabry disease | 16 May, 2027 | Active |
| US9000011 | Methods for treatment of Fabry disease | 16 May, 2027 | Active |
| US9480682 | Methods for treatment of Fabry disease | 16 May, 2027 | Active |
| US9987263 | Methods for treatment of Fabry disease | 16 May, 2027 | Active |
Latest Legal Activities on Amicus Therap Us's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amicus Therap Us.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 17 Jun, 2024 | US10925866 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Jun, 2024 | US10874655 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Jun, 2024 | US10874657 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Jun, 2024 | US10874656 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 05 Jun, 2024 | US10874656 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 05 Jun, 2024 | US10874657 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 05 Jun, 2024 | US10874655 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 May, 2024 | US10857142 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 May, 2024 | US10857141 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 22 May, 2024 | US10857212 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 15 May, 2024 | US10849889 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 May, 2024 | US10849890 |
|
Withdrawal of Application for PTE
Critical
| 13 May, 2024 | US9000011 |
| Letter from FDA or Dept of Agriculture re PTE application | 08 May, 2024 | US10208299 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 10 Apr, 2024 | US10813921 |
Amicus Therap Us Drug Patents' Oppositions Filed in EPO
Amicus Therap Us drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on May 31, 2022, by Gill Jennings & Every Llp. This opposition was filed on patent number EP17714100A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
 | |||
| EP17714100A | May, 2022 | Teva Pharmaceutical Industries Ltd | Granted and Under Opposition |
| EP17714100A | May, 2022 | Gill Jennings & Every LLP | Granted and Under Opposition |
Amicus Therap Us's Family Patents
Amicus Therap Us drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 40.4% of its total global patent coverage. 1 country has all of their patents expired or invalidated which has opened up potential generic launch opportunities in this particular country. Click
below to unlock the full patent family tree.
Amicus Therap Us Drug List
Given below is the complete list of Amicus Therap Us's drugs and the patents protecting them.
1. Galafold
Galafold is protected by 61 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US11833164 | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
11 Jan, 2042
(17 years from now)
| Active |
| US11633388 | Methods of treating Fabry patients having renal impairment |
25 Mar, 2039
(14 years from now)
| Active |
| US11622962 | Methods of treating Fabry patients having renal impairment |
17 Mar, 2039
(14 years from now)
| Active |
| US11642334 | Methods of treating Fabry patients having renal impairment |
20 Feb, 2039
(14 years from now)
| Active |
| US11826360 | Methods of treating Fabry patients having renal impairment |
16 Feb, 2039
(14 years from now)
| Active |
| US11357784 | Use of migalastat for treating Fabry disease in pregnant patients |
06 Feb, 2039
(14 years from now)
| Active |
| US11903938 | Methods of treating Fabry patients having renal impairment |
17 Aug, 2038
(13 years from now)
| Active |
| US10251873 | Methods of treating fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10471053 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10792278 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10792279 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10799491 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10806727 | Methods of treating fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10849889 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10849890 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10857141 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10857142 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10874655 | Methods of treating fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10874656 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10874657 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11278536 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11278537 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11278538 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11278539 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11278540 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11304940 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11357761 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11357762 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11357763 | Methods of treating fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11357764 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11357765 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11376244 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11389436 | Methods of treating fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11389437 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11426396 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11458128 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11612593 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11612594 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11633387 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11666564 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11786516 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US11813255 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US12042488 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US12042489 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US12042490 | Methods of treating Fabry patients having renal impairment |
30 May, 2038
(13 years from now)
| Active |
| US10076514 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
15 Mar, 2037
(12 years from now)
| Active |
| US11234972 | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
15 Mar, 2037
(12 years from now)
| Active |
| USRE48608 | Method to predict response to pharmacological chaperone treatment of diseases |
20 Oct, 2031
(6 years from now)
| Active |
| US10813921 | Method to predict response to pharmacological chaperone treatment of diseases |
12 Feb, 2029
(4 years from now)
| Active |
| US8592362 | Method to predict response to pharmacological chaperone treatment of diseases |
12 Feb, 2029
(4 years from now)
| Active |
| US9095584 | Method to predict response to pharmacological chaperone treatment of diseases |
12 Feb, 2029
(4 years from now)
| Active |
| US10525045 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
28 Apr, 2028
(3 years from now)
| Active |
| US10925866 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
28 Apr, 2028
(3 years from now)
| Active |
| US11033538 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
28 Apr, 2028
(3 years from now)
| Active |
| US9999618 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
28 Apr, 2028
(3 years from now)
| Active |
| US10383864 | Methods for treatment of Fabry disease |
16 May, 2027
(2 years from now)
| Active |
| US10406143 | Methods for treatment of fabry disease |
16 May, 2027
(2 years from now)
| Active |
| US11241422 | Methods for treatment of Fabry disease |
16 May, 2027
(2 years from now)
| Active |
| US9000011 | Methods for treatment of Fabry disease |
16 May, 2027
(2 years from now)
| Active |
| US9480682 | Methods for treatment of Fabry disease |
16 May, 2027
(2 years from now)
| Active |
| US9987263 | Methods for treatment of Fabry disease |
16 May, 2027
(2 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Galafold's drug page
2. Opfolda
Opfolda is protected by 7 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10857212 | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
12 Aug, 2037
(12 years from now)
| Active |
| US11278601 | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
29 Dec, 2036
(12 years from now)
| Active |
| US10208299 | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
30 Sep, 2035
(10 years from now)
| Active |
| US10961522 | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
30 Sep, 2035
(10 years from now)
| Active |
| US11753632 | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
30 Sep, 2035
(10 years from now)
| Active |
| US10512677 | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
07 Mar, 2033
(8 years from now)
| Active |
| US11278599 | High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
07 Mar, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Opfolda's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List